RecruitingNCT06388967

Pancreatic Cancer Detection Consortium

Early Detection of Pancreatic Cancer: Prospective Study


Sponsor

City of Hope Medical Center

Enrollment

2,000 participants

Start Date

Mar 15, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)
  • Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
  • Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)

Exclusion Criteria1

  • Lack of written informed consent.

Interventions

DIAGNOSTIC_TESTPANcreatic cancer Exosome Early detectiON (PANXEON)

This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it


Locations(11)

Translational Genomics Research Institute

Phoenix, Arizona, United States

Honorhealth

Scottsdale, Arizona, United States

City of Hope Medical Center

Monrovia, California, United States

Hoag Center

Newport Beach, California, United States

OSF HealthCare

Peoria, Illinois, United States

Ochsner Medical Center

Jefferson, Louisiana, United States

Atlantic Health System

Morristown, New Jersey, United States

Piedmont Medical Center

Rock Hill, South Carolina, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Nagoya University

Nagoya, Japan

Asan Medical Center

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06388967


Related Trials